Bedfont’s life saving success leads to NOxBOX Limited.

Bedfont Scientific Limited has created a subsidiary as part of its long term development and expansion plans. The new company NOxBOX Limited will concentrate on its hugely successful range of Inhaled Nitric Oxide monitoring systems.

Bedfont Scientific Limited, established in 1976 in Harrietsham, Kent, specialises in exhaled breath and gas monitors which are used in the medical industry. The NOxBOX range was introduced by Bedfont in 1992 and is used to deliver and monitor inhaled nitric oxide (iNO) therapy.

iNO therapy is mainly used in intensive care units (ICU) to aid in the therapeutic care of premature babies and patients under severe respiratory distress. Using iNO therapy allows the blood supply to pick up oxygen from the lungs more readily by dilating the pulmonary arteries, making it the ideal method of treatment for pulmonary hypertension and other conditions that can lead to severe breathing difficulties. It is also the only iNO therapy monitor that can be used during transport, making it ideal for ambulances.

The new subsidiary company will focus on increasing awareness of the NOxBOX product and associated healthcare benefits to improve market share in the UK, Europe and further develop its customer base across the global market, while its parent company Bedfont Scientific will concentrate on developing new products and increasing use of its wide range of existing breath and gas monitoring systems.

Jason Smith, Bedfont Scientific’s General Manager, says,

“The success of the NOxBOX range has led us to what we feel is a natural progression that will further ensure the continued high levels of quality and service for our customers.

“Our aim for NOxBOX Limited is to grow the customer base globally, continuing to save lives, one breath at a time.”